New REMS Education Program Helps Increase Safe, Responsible Use of Opioid Analgesics for Pain Relief
Intensive Measurement Tools Verify Positive Outcomes on Prescribing Behavior and Patient Care
The REMEDIES program was developed to meet the goals of the class-wide
Risk Evaluation and Mitigation Strategy (REMS) for extended-release and
long-acting opioid analgesics, as required by the
“REMEDIES is a novel educational platform for prescribers and is
intended to improve the quality of care for opioid-tolerant pain
The REMEDIES initiative was jointly provided by
“As a leader in prescription pain medicine,
The REMEDIES curriculum incorporates a variety of tools that include live symposia, interactive web-based activities, a three-stage performance improvement program, and a series of three patient screening and education activities that help healthcare providers navigate the clinical challenge of opioid prescribing.
REMEDIES Results Show Positive Impact on Prescribers, Patients
REMEDIES program goals include reaching more than 10,000 primary care physicians, pain specialists, nurse practitioners, physician assistants and other professionals involved in pain management; delivering educational content in three hours or less; and achieving continuing educational outcomes of Levels 1 through 7 as defined by the Moore Scale. The Moore Scale is a framework for continuing education programs that measures participation, satisfaction, learning, performance, patient health and community health, and it incorporates noncertified online educational resources for healthcare professionals and patients.
Outcome-assessment tools were developed to accurately measure the
effects of knowledge, competence, performance and patient outcomes
throughout all activities. The tools also measure reliability of
self-reported clinician changes in confidence and practice behaviors
with actual patient outcomes. Results through
- Participation (Level 1) Outcomes: More than 21,000 participants (more than twice the goal), nearly 4,500 content completions, 4,231 evaluations and certificates, and more than 24,000 resource center visits.
- Satisfaction (Level 2) Outcomes: Evaluations found 98% of participants Agree or Strongly Agree that learning objectives were met, 97% Agree or Strongly Agree that faculty members were effective, and 97% Agree or Strongly Agree that activities were free from bias.
- Learning/Competence (Levels 3 and 4) Outcomes: Participants experienced a 39% increase in knowledge of curriculum topics and a 43% increase in confidence/competence.
- Performance (Level 5) Outcomes: Participants demonstrated an average 67% increase in applying the practice strategies learned.
Patient Health(Level 6) Outcomes: 100 of 200 physicians enrolled met the criteria for opioid prescribing, and physician behavior increased 96% from stages A to C, with more than 300 patients documented in the ongoing program.
Community Health(Level 7) Outcomes: Employees seeking medical care for 1 of 20 identified pain conditions increased 12.8%, with an 8.3% decrease in payments across 20 ICD-9 (insurance) codes and a collective saving of more than $58,000among patient participants.
Partners collaborating in the development of REMEDIES included
For more information about Mallinckrodt’s presence at PAINWeek, contact Mallinckrodt Medical Information at 1.800.788.7898 or at email@example.com. Find more information about PAINWeek at painweek.org.
Rhonda Sciarra, 314-654-8618
Meredith Fischer, 314-654-6595
Senior Vice President, Communications
John Moten, 314-654-6650
Vice President, Investor Relations